Pulmonary Arterial Hypertension


Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.


Effect of Vitamin D in Experimental Pulmonary Arterial Hypertension in Rats: Possible Role of eNOS-mediated Signalling Pathways


25 April 2023


European Cardiology Review 2023;18:e28.

Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator


European Cardiology Review 2018;13(1):35–7.

Direct Oral Anticoagulants: A Quick Guide


European Cardiology Review 2017;12(1):40–5.

Pulmonary Hypertension


European Cardiology Review 2015;10(1):9–11